The use of experimental design in the optimization of risperidone biodegradable nanoparticles: in vitro and in vivo study.
The aim of this study was optimization of risperidone (model drug) biodegradable nanoparticles utilizing emulsion-solvent evaporation technique. Box-Behnken design was adopted to optimize the preparation process. Optimized nanoparticles were characterized for surface morphology using scanning electron microscope. Pharmacokinetic parameters were compared with the marketed tablets. Results revealed that the optimized formula showed 297.37 nm, 85.12%, and 59.79% for Y1, Y2, and Y3, respectively. Optimized formula showed significant improved bioavailability compared with marketed tablets. Successful achievement of prolonged risperidone release with improved bioavailability is expected to maximize patients' adherence to their antipsychotic drug therapy and to minimize risk of relapse during maintenance therapy.